Replies to post #99672 on Ayala Pharmaceuticals Inc (ADXS)

[Bourbon_on_my_cornflakes]

ADXS will be burning cash at $10m qtr

Research and development expenses for the second quarter of fiscal year 2019 were $6.0 million, compared with $10.4 million for the second quarter of fiscal year 2018. The $4.4 million decrease was primarily attributable to cost controls initiated in the second half of fiscal year 2018. In addition, there was a decrease in clinical trial expenses resulting from the partial clinical hold on AIM2CERV and the winding down of several older studies, partially offset by an increase in expenses related to the startup costs associated with the commencement of the Phase 1/2 ADXS-HOT clinical trial.

So, hold over, burn increases
No more Gen 1 studies to toss on garbage fail pile.
More HOT expenses.

BK by year-end unless Keen pulls a Hail Mary funding.